ICU Medical (NASDAQ:ICUI) Updates FY 2024 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.400-5.100 for the period, compared to the consensus estimate of 4.730. The company issued revenue guidance of -.

ICU Medical Trading Up 1.1 %

ICU Medical stock opened at $101.77 on Wednesday. The stock has a market cap of $2.48 billion, a P/E ratio of -82.74 and a beta of 0.72. ICU Medical has a fifty-two week low of $78.28 and a fifty-two week high of $212.43. The firm’s fifty day moving average price is $100.79 and its 200-day moving average price is $97.08. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.06 and a current ratio of 2.53.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.39. The firm had revenue of $587.86 million for the quarter, compared to analysts’ expectations of $564.77 million. ICU Medical had a positive return on equity of 6.35% and a negative net margin of 1.31%. Equities research analysts forecast that ICU Medical will post 3.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, KeyCorp boosted their price target on shares of ICU Medical from $134.00 to $136.00 and gave the stock an overweight rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $123.00.

Insider Buying and Selling

In other ICU Medical news, VP Daniel Woolson sold 791 shares of ICU Medical stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $98.27, for a total transaction of $77,731.57. Following the transaction, the vice president now directly owns 13,980 shares of the company’s stock, valued at $1,373,814.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director George A. Lopez sold 1,890 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $104.22, for a total value of $196,975.80. Following the transaction, the director now owns 317,753 shares in the company, valued at $33,116,217.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel Woolson sold 791 shares of ICU Medical stock in a transaction on Friday, March 15th. The stock was sold at an average price of $98.27, for a total transaction of $77,731.57. Following the completion of the transaction, the vice president now directly owns 13,980 shares in the company, valued at $1,373,814.60. The disclosure for this sale can be found here. Insiders sold 24,262 shares of company stock worth $2,545,532 in the last quarter. 6.70% of the stock is owned by insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.